RxDoctor Payments Data

Sirish Sanaka, MD

Gastroenterology · Greenville, NCNPI 1902017452

Payments from drug & device makers

$7,181in general payments, 2019–2025

Across 349 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$845
  • Takeda Pharmaceuticals U.S.A., Inc.$680
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$624
  • Pfizer$417
  • Johnson & Johnson$392
  • plus $3K from 36 others

What the payments were for

  • Travel & lodging$84512%
  • Food & beverage$6,19286%
  • Education$921%
  • Gifts$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,181 in reported general payments places this provider in the 65th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$92,622
Medicare patients
331
Services billed
949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf)Adalimumab12$81,410
LinzessLinaclotide25$22,717
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates117$8,206
Mesalamine14$5,043
Dexlansoprazole DrDexlansoprazole12$4,727
ClenpiqSod Picosulf/Mag Ox/Citric Ac27$4,638
Sucralfate52$3,988
SutabSod Sulf/Pot Chloride/Mag Sulf14$2,256
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C13$1,883
Omeprazole133$1,559
Pantoprazole Sodium142$1,505
Famotidine51$532
Dicyclomine Hcl29$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Linzess$1,719$104,12737 claims
Ferring Pharmaceuticals Inc.Clenpiq$203$4,63827 claims
Braintree Laboratories, Inc.Sutab$129$2,25614 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$624$1,88313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →